Related Experiment Video

Updated: Sep 26, 2026

Performing and Processing FNA of Anterior Fat Pad for Amyloid
09:41

Performing and Processing FNA of Anterior Fat Pad for Amyloid

Published on: October 30, 2010

Clinical experience with cardiac amyloidosis

Ann Goeminne1, Luc Missault, Frank Bauwens

  • 1Departments of Cardiology, St. Jan Hospital, Brugge, Belgium.

Acta Cardiologica
|April 29, 2003
PubMed

Insights

Acquired cardiac amyloidosis, a serious heart condition, has a poor prognosis. Most patients diagnosed with heart failure due to acquired amyloidosis die within a year, even with optimal treatment.

Area of Science:

  • Cardiology
  • Systemic Diseases
  • Amyloidosis Research

Background:

  • Amyloidosis is a systemic disease that can significantly impact cardiac function.
  • Cardiac involvement in amyloidosis often leads to heart failure.
  • Understanding the prognosis of cardiac amyloidosis is crucial for patient management.

Purpose of the Study:

  • To retrospectively analyze patients with major cardiac amyloidosis.
  • To evaluate the clinical characteristics, diagnostic work-up, and treatment outcomes.
  • To determine the prognosis of acquired cardiac amyloidosis.

Main Methods:

  • Retrospective study of eight patients diagnosed with cardiac amyloidosis between 1997 and 2000.
  • Analysis of clinical, electrocardiographic, and echocardiographic data.
  • Review of treatment modalities for heart failure.

Main Results:

  • All eight patients presented with heart failure due to cardiac amyloidosis.
  • Seven of eight patients with acquired amyloidosis (AL and AA types) died within one year.
  • Death resulted from intractable cardiac failure, including systolic and diastolic left ventricular dysfunction.
  • One patient with hereditary amyloidosis survived after liver transplantation.

Conclusions:

  • Acquired cardiac amyloidosis carries an ominous prognosis.
  • Optimal medical treatment for heart failure did not improve survival rates.
  • Advanced disease stage at presentation likely contributes to the poor prognosis.
Abstract

More Related Videos

Transthoracic Echocardiographic Examination in the Rabbit Model14:46

Transthoracic Echocardiographic Examination in the Rabbit Model

Published on: June 1, 2019

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
Myocarditis II: Clinical Features and Diagnostic Tests01:27

Myocarditis II: Clinical Features and Diagnostic Tests

Myocarditis is an inflammation of the heart muscle. The symptoms vary widely, encompassing asymptomatic presentations to severe, acute manifestations.Clinical PresentationAsymptomatic cases: In some instances, myocarditis may be asymptomatic, with the infection resolving without intervention. These cases often go undetected unless discovered incidentally through diagnostic imaging or tests conducted for other reasons.General Early Symptoms: Early symptoms of myocarditis are non-specific and can...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...